Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol
NCT ID: NCT00380276
Last Updated: 2008-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
1000 participants
INTERVENTIONAL
2006-09-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Open Label Arm
Treatment is open-label
MPC-7869
800 mg BID Oral dosing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MPC-7869
800 mg BID Oral dosing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have had a diagnosis of probable Alzheimer's disease.
* Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
* Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
* Female subjects must be surgically sterile or postmenopausal for \> 1 year.
* Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.
Exclusion Criteria
* Chronic or acute renal, hepatic or metabolic disorder.
* Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Myrexis Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Myriad Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mark Laughlin, MD
Role: STUDY_DIRECTOR
Myrexis Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabaster, Alabama, United States
Huntsville, Alabama, United States
Phoenix, Arizona, United States
Sun City, Arizona, United States
Tucson, Arizona, United States
Costa Mesa, California, United States
Irvine, California, United States
Lafayette, California, United States
Laguna Hills, California, United States
Long Beach, California, United States
Rancho Mirage, California, United States
Sacramento, California, United States
San Diego, California, United States
San Francisco, California, United States
Vista, California, United States
Danbury, Connecticut, United States
Darien, Connecticut, United States
New Haven, Connecticut, United States
Washington D.C., District of Columbia, United States
Deerfield Beach, Florida, United States
Fort Meyers, Florida, United States
Fort Myers, Florida, United States
Hollywood, Florida, United States
Jacksonville, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Sunrise, Florida, United States
Tampa, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Chicago, Illinois, United States
Fort Wayne, Indiana, United States
Indianapolis, Indiana, United States
Lexington, Kentucky, United States
Baltimore, Maryland, United States
Glen Burnie, Maryland, United States
Boston, Massachusetts, United States
West Yarmouth, Massachusetts, United States
Ann Arbor, Michigan, United States
Grand Rapids, Michigan, United States
Rochester, Minnesota, United States
St Louis, Missouri, United States
Lebanon, New Hampshire, United States
Kenilworth, New Jersey, United States
Morristown, New Jersey, United States
Princeton, New Jersey, United States
Stratford, New Jersey, United States
Albuquerque, New Mexico, United States
Albany, New York, United States
Brooklyn, New York, United States
Elmsford, New York, United States
New York, New York, United States
Olean, New York, United States
Rochester, New York, United States
Syracuse, New York, United States
Durham, North Carolina, United States
Raleigh, North Carolina, United States
Centerville, Ohio, United States
Columbus, Ohio, United States
Toledo, Ohio, United States
Oklahoma City, Oklahoma, United States
Eugene, Oregon, United States
Portland, Oregon, United States
Jenkintown, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
Scotland, Pennsylvania, United States
East Providence, Rhode Island, United States
Beaufort, South Carolina, United States
Charleston, South Carolina, United States
Greer, South Carolina, United States
Memphis, Tennessee, United States
Nashville, Tennessee, United States
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
Ogden, Utah, United States
Salt Lake City, Utah, United States
Bennington, Vermont, United States
Alexandria, Virginia, United States
Charlottesville, Virginia, United States
Virginia Beach, Virginia, United States
Middleton, Wisconsin, United States
Milwaukee, Wisconsin, United States
Winnepeg, Manitoba, Canada
Halifax, Nova Scotia, Canada
Kingston, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Regina, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPC-7869-05-009
Identifier Type: -
Identifier Source: org_study_id